Molecular Biology of the Cell click for CBE Life Science Education Page

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Originally published as MBC in Press, 10.1091/mbc.E02-05-0252 on August 6, 2002
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
E02-05-0252v1
13/10/3431    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Russell, J. S.
Right arrow Articles by Tofilon, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Russell, J. S.
Right arrow Articles by Tofilon, P. J.

Vol. 13, Issue 10, 3431-3440, October 2002

Radiation-induced Activation of Nuclear Factor-kappa B Involves Selective Degradation of Plasma Membrane-associated Ikappa Balpha

Jeffery S. Russell,*dagger and Philip J. Tofilondagger Dagger

 *Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; and  dagger Molecular Radiation Therapeutics Branch, Radiation Oncology Science Program, National Cancer Institute, Bethesda, Maryland 20892

In contrast to nuclear factor-kappa B (NF-kappa B) activation by tumor necrosis factor-alpha (TNF-alpha ), the specific processes involved in the activation of this transcription factor by ionizing radiation (IR) have not been completely defined. According to the classical paradigm, a critical event in NF-kappa B activation is the degradation of Ikappa Balpha . Data presented herein show that, in contrast to treatment with TNF-alpha , IR-induced NF-kappa B activation was not accompanied by degradation of Ikappa Balpha in the U251 glioblastoma cell line as determined in whole cell lysates. However, treatment with the proteosome inhibitor MG-132 inhibited NF-kappa B activation induced by IR, suggesting that Ikappa Balpha degradation was a critical event in this process. To reconcile these results, U251 cell lysates were separated into soluble and insoluble fractions and Ikappa Balpha levels evaluated. Although Ikappa Balpha was found in both subcellular fractions, treatment with IR resulted in the degradation of Ikappa Balpha only in the insoluble fraction. Further subcellular fractionation suggested that the IR-sensitive, insoluble pool of Ikappa Balpha was associated with the plasma membrane. These data suggest that the subcellular location of Ikappa Balpha is a critical determinant in IR-induced NF-kappa B activation.


Dagger Corresponding author. E-mail address: tofilonp{at}mail.nih.gov.


Molecular Biology of the Cell
Vol. 13, 3431-3440, October 2002
Copyright © 2002 by The American Society for Cell Biology



This article has been cited by other articles:


Home page
Cancer Res.Home page
M. Zheng, S. E. Morgan-Lappe, J. Yang, K. M. Bockbrader, D. Pamarthy, D. Thomas, S. W. Fesik, and Y. Sun
Growth Inhibition and Radiosensitization of Glioblastoma and Lung Cancer Cells by Small Interfering RNA Silencing of Tumor Necrosis Factor Receptor-Associated Factor 2
Cancer Res., September 15, 2008; 68(18): 7570 - 7578.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
U. von Holzen, A. Pataer, U. Raju, D. Bocangel, S. A. Vorburger, Y. Liu, X. Lu, J. A. Roth, B. B. Aggarwal, G. N. Barber, et al.
The Double-Stranded RNA-Activated Protein Kinase Mediates Radiation Resistance in Mouse Embryo Fibroblasts through Nuclear Factor {kappa}B and Akt Activation
Clin. Cancer Res., October 15, 2007; 13(20): 6032 - 6039.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Sun, D. K. St. Clair, F. Fang, G. W. Warren, V. M. Rangnekar, P. A. Crooks, and W. H. St. Clair
The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-{kappa}B inhibition and enhanced by the presence of PTEN
Mol. Cancer Ther., September 1, 2007; 6(9): 2477 - 2486.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Xiao, C. E. Inal, V. I. Parekh, C.-M. Chang, and M. H. Whitnall
5-Androstenediol Promotes Survival of {gamma}-Irradiated Human Hematopoietic Progenitors through Induction of Nuclear Factor-{kappa}B Activation and Granulocyte Colony-Stimulating Factor Expression
Mol. Pharmacol., August 1, 2007; 72(2): 370 - 379.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. G. Izzo, U. Malhotra, T.-T. Wu, R. Luthra, A. M. Correa, S. G. Swisher, W. Hofstetter, K.S. C. Chao, M.-C. Hung, and J. A. Ajani
Clinical Biology of Esophageal Adenocarcinoma after Surgery Is Influenced by Nuclear Factor-{kappa}B Expression
Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1200 - 1205.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. Szotowski, S. Antoniak, P. Goldin-Lang, Q.-V. Tran, K. Pels, P. Rosenthal, V. Y. Bogdanov, H.-H. Borchert, H.-P. Schultheiss, and U. Rauch
Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells
Cardiovasc Res, March 1, 2007; 73(4): 806 - 812.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. M. Wilczynska, S. M. Gopalan, M. Bugno, A. Kasza, B. S. Konik, L. Bryan, S. Wright, I. Griswold-Prenner, and T. Kordula
A Novel Mechanism of Tissue Inhibitor of Metalloproteinases-1 Activation by Interleukin-1 in Primary Human Astrocytes
J. Biol. Chem., November 17, 2006; 281(46): 34955 - 34964.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. G. Izzo, U. Malhotra, T.-T. Wu, J. Ensor, R. Luthra, J. H. Lee, S. G. Swisher, Z. Liao, K.S. C. Chao, W. N. Hittelman, et al.
Association of Activated Transcription Factor Nuclear Factor {kappa}B With Chemoradiation Resistance and Poor Outcome in Esophageal Carcinoma
J. Clin. Oncol., February 10, 2006; 24(5): 748 - 754.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]